RxDoctor Payments Data

Robin Walker, MD

Family Medicine · Wichita, KSNPI 1891917209

Payments from drug & device makers

$4,409in general payments, 2019–2025

Across 280 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$617
  • Pfizer$389
  • Lilly USA, LLC$341
  • Bayer$291
  • AbbVie$271
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,409 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$108,505
Medicare patients
308
Services billed
11,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$62,982
JardianceEmpagliflozin28$39,429
MounjaroTirzepatide23$23,718
FarxigaDapagliflozin Propanediol22$20,803
EliquisApixaban26$19,920
XareltoRivaroxaban13$16,878
InvokanaCanagliflozin12$6,830
Pregabalin36$2,866
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen107$2,738
Gabapentin79$1,928
Testosterone12$1,618
SynthroidLevothyroxine Sodium27$1,576
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,560
Amlodipine Besylate231$1,465
Atorvastatin Calcium270$1,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,135$62,98269 claims
Boehringer IngelheimJardiance$35$39,42928 claims
Lilly USA, LLCMounjaro$341$23,71823 claims
Johnson & JohnsonXarelto, Invokana$92$23,70825 claims
AstraZenecaFarxiga$617$20,80322 claims
PfizerEliquis$389$19,92026 claims
AbbVieSynthroid$271$1,57627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →